Tuberculosis Clinical Trial Update and the Current Anti-Tuberculosis Drug Portfolio

Author(s): Juan Carlos Palomino, Anandi Martin

Journal Name: Current Medicinal Chemistry

Volume 20 , Issue 30 , 2013

Become EABM
Become Reviewer
Call for Editor


Tuberculosis (TB), an ongoing public health threat, is worsened by the emergence of drug resistance. With an estimated 630000 cases per year of multidrug resistant (MDR)-TB, and 9% of those being extensively drug resistant (XDR)-TB, there is an urgent need for new and more effective anti-TB drugs. New TB treatment regimens should be able to shorten the duration of therapy that currently takes at least six months. The non-compliance with this long treatment duration is one of the reasons for the development of drug resistance. In spite of the difficulties and alleged lack of interest from the pharmaceutical industry for the discovery and development of new antibiotics, several new or repurposed drugs are being evaluated in clinical trials. This review article summarizes the information available and presents an update on the drugs currently in clinical trials for TB and briefly introduces some new compounds in pre-clinical development.

Keywords: Antibiotics, clinical trials, drug development, drug resistance, tuberculosis.

open access plus

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [3785 - 3796]
Pages: 12
DOI: 10.2174/09298673113209990166

Article Metrics

PDF: 83